Ashley Hall - Aug 28, 2023 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (RPHM)

Role
Chief Development Officer
Signature
/s/ Jennifer P. Lam, Attorney-in-Fact
Stock symbol
RPHM
Transactions as of
Aug 28, 2023
Transactions value $
-$69,933
Form type
4
Date filed
8/29/2023, 05:04 PM
Previous filing
Dec 13, 2022
Next filing
Sep 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPHM Common Stock Options Exercise $28.1K +15.6K +39.46% $1.80 55.2K Aug 28, 2023 Direct F1
transaction RPHM Common Stock Sale -$98.1K -15.6K -28.29% $6.28 39.6K Aug 28, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPHM Stock option (right to buy) Options Exercise $0 -15.6K -12.5% $0.00 109K Aug 28, 2023 Common Stock 15.6K $1.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.24 to $6.44, inclusive. The reporting person undertakes to provide any security holder of Reneo Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.